[Interaction of sulfinpyrazone (Anturan) and glibenclamide (Euglucon) in type II diabetic patients].
In a randomised double blind study on 19 with glibenclamide well controlled diabetics of type II the possible interaction between sulfinpyrazone (Anturan) and glibenclamide was studied with the help of the artificial endocrine pancreas. The trial substance in a dose of 800 mg/die or placebo were used over a period of 70 days. During the trial period and at the end of it there were no significant differences in the sulfinpyrazone group as compared to the placebo group concerning the metabolic control of the diabetic condition. It is therefore justified to assume that there exists no interaction between sulfinpyrazone and glibenclamide in this regard. The dosage of sulfinpyrazone used in this trial was well tolerated by all patients and no side effects were observed.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D004347:Drug Interactions; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007332:Insulin Infusion Systems; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013442:Sulfinpyrazone / Q000008:administration & dosage / Q000627:therapeutic use*
D010919:Placebos; D005905:Glyburide; D013442:Sulfinpyrazone
Interaktionsstudie mit Sulfinpyrazon (Anturan) und Glibenclamid (Euglucon) bei Typ-II-Diabetikern.